Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235112 | 0.79 | CYP1A2 (0.52) | PPARDTSHRALDH1A1CYP1A2TDP1 | |
| SCHEMBL11203182 | 0.79 | TSHR (0.52) | PPARDTSHRALDH1A1LMNACA12 | |
| SCHEMBL11333177 | 0.79 | TSHR (0.41) | PPARDTSHRCA12CA1CA2 | |
| SCHEMBL28215665 | 0.77 | TSHR (0.53) | PPARDTSHRALDH1A1LMNACYP1A2 | |
| SCHEMBL15951772 | 0.75 | DGKA (0.47) | PPARDTSHRCYP1A2 | |
| SCHEMBL24475840 | 0.74 | PPARD (0.54) | PPARDTSHRCA12CA1CA2 | |
| SCHEMBL2383184 | 0.74 | PPARD (0.54) | PPARDTSHRALDH1A1TDP1 | |
| SCHEMBL2990604 | 0.74 | PPARD (0.54) | PPARDTSHRALDH1A1CA12CA1 | |
| SCHEMBL93600 | 0.74 | — | — | |
| SCHEMBL4931741 | 0.74 | CYP1A2 (0.50) | PPARDTSHRALDH1A1CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309721-B2 | Immunosuppressants for treating diseases and conditions of bone marrow, organ and tissue transplant rejection; chemotherapeutic drug for cancers; antiinflammatory agents for rheumatoid arthritis; activate the production of lymphocyte; 2-Amino-4-(4-(octylphenyl))butanol, O-phosphate | MERCK + CO., INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | DOHERTY GEORGE A | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | ADGRE5, EDNRA, ADGRF1 | PPARD 466/4885TSHR 724/4885ALDH1A1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.